Affirm Holdings, Inc. Share Price Target ‘$36.72’, now 11.2% Upside Potential

DirectorsTalk Interviews

Affirm Holdings, Inc. with ticker code (AFRM) have now 15 market analysts covering the stock. The analyst consensus now points to a rating of ‘hold’. The target price High/Low ranges between $65.00 and $20.00 calculating the mean target share price we have $36.72. (at the time of writing). Now with the previous closing price of $33.03 this now indicates there is a potential upside of 11.2%. Also worth taking note is the 50 day moving average now sits at $33.77 while the 200 day moving average is $31.11. The company has a market capitalization of 9.98B. The stock price is currently at: $32.28 USD

The potential market cap would be $11,093,324,747 based on the market consensus.

The company has a dividend yield of 0.89%. Other points of data to note are a P/E ratio of -, revenue per share of $6.90 and a -5.8% return on assets.

Affirm Holdings, Inc. provides a platform for digital and mobile-first commerce. The Company’s platform comprises three elements: point-of-sale payment solutions for consumers, merchant commerce solutions, and a consumer-focused app. Its point-of-sale solutions allow consumers to pay for purchases in fixed amounts without deferred interest, late fees, or penalties. Its merchant commerce solutions offer commerce enablement, demand generation, and customer acquisition tools. Its consumer-focused app provides Affirm products, which consumers can use to manage payments, open a high-yield savings account, and access a personalized marketplace. The Company’s platform provides consumer and merchant features. Its consumer features include checkout, consumer borrowing, virtual card, affirm app and marketplace and Affirm debit+ card. Its merchant features include affirm at Checkout, merchant dashboard, analytics, client success support, affirm app, and returns management, among others.

Share on:

Latest Company News

EDX Medical raises £2.7m to expand employee health screening service

EDX Medical has raised approximately £2.7m through a share subscription to support the expansion of its employee health screening service, as discussions progress with several major UK employers.

GSK gains priority FDA review for Jemperli in rectal cancer

GSK says the US FDA has accepted Jemperli for priority review in previously untreated stage II and III locally advanced rectal cancer.

Cora Gold secures interim renewal of Sanankoro II exploration permit

Cora Gold has secured the first interim renewal of the Sanankoro II exploration permit in south Mali as it progresses towards full permitting.

Likewise Group completes purchase of Corby distribution hub

Likewise Group plc has completed the freehold acquisition of a new Corby distribution hub for £9.57 million, with operations expected from January 2027.

Adaptix secures US Federal sales channel for Ortho350

Adaptix has secured a dedicated US federal sales channel for the Ortho350 through an exclusive reseller agreement with Spartan Medical.

MERLYN broadens ARYSTO range with new stone shower tray

MERLYN is expanding its premium ARYSTO range with ARYSTO Stone, a new shower tray launching in October 2026 with a focus on design, safety and practicality.

    Search